Konradin F. Müskens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Konradin F. Müskens has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Brigit M. Te Pas
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
19 shared publications - Mirjam E. Belderbos
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
19 shared publications - Aniek O. de Graaf
Laboratory of Hematology-Department of Laboratory Medicine, Radboud UMC, Nijmegen, The Netherlands
18 shared publications - Anne P. J. de Pagter
Department of Pediatrics, Division of Stem Cell Transplantation, Willem-Alexander Children’s Hospital, Leiden University Medical Center, Leiden, The Netherlands
18 shared publications - Arjan C. Lankester
Willem-Alexander Children’s Hospital, Leiden University Medical Center, Leiden, the Netherlands
18 shared publications - Caroline A. Lindemans
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
18 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Characteristics of total and matched cohorts
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Characteristics of total and matched cohorts
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Supplementary Table S2 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Supplementary Table S2 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Additional visualizations of CRP measurements
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Additional visualizations of CRP measurements
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Additional details on CH mutations in HCT recipients and controls
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Additional details on CH mutations in HCT recipients and controls
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Overview of screening and inclusion
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Overview of screening and inclusion
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Effect of HCT and different related timespans on CH prevalence
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Effect of HCT and different related timespans on CH prevalence
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Supplementary Table S1 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Supplementary Table S1 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Clonal hematopoiesis gene panel
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
Clonal hematopoiesis gene panel
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. In this study, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT survivors and 258 nontransplanted controls. CH was detected in 16% of HCT recipients and 8% of controls at variant allele frequencies of 0.01 to 0.31. Mutations were predominantly in DNMT3A (80%) and TET2 (20%). Older hematopoietic age (OR: 1.07; P < 0.001) and the HCT procedure (OR: 2.53; P = 0.02) independently increased the risk of CH, indicating both aging- and transplantation-induced effects. Large clones (variant allele frequency >0.10) were found exclusively in HCT recipients. Notably, CH was also detected within 15 years after a cord blood HCT. Inflammatory processes around graft infusion were associated with CH presence. Future studies are required to track the evolution of posttransplant CH and its impact on future cardiovascular diseases, second malignancies, and overall survival.Significance:As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies are crucial to understand the clinical implications of posttransplant CH in this young population.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation
In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. In this study, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT survivors and 258 nontransplanted controls. CH was detected in 16% of HCT recipients and 8% of controls at variant allele frequencies of 0.01 to 0.31. Mutations were predominantly in DNMT3A (80%) and TET2 (20%). Older hematopoietic age (OR: 1.07; P < 0.001) and the HCT procedure (OR: 2.53; P = 0.02) independently increased the risk of CH, indicating both aging- and transplantation-induced effects. Large clones (variant allele frequency >0.10) were found exclusively in HCT recipients. Notably, CH was also detected within 15 years after a cord blood HCT. Inflammatory processes around graft infusion were associated with CH presence. Future studies are required to track the evolution of posttransplant CH and its impact on future cardiovascular diseases, second malignancies, and overall survival.Significance:As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies are crucial to understand the clinical implications of posttransplant CH in this young population.
- Top Cited PapersOpen Access
- 17 February 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 613-623
Single-cell multiomic atlas of healthy pediatric bone marrow reveals age-dependent differences in lineage differentiation driven by stromal signaling
Childhood is a critical period for hematopoietic development and susceptibility to hematologic disease. Here we generated a multimodal single-cell atlas of healthy human bone marrow, capturing mRNA and surface protein expression in 90,710 cells, including over 20,000 hematopoietic stem and progenitor cells (HSPC) and mesenchymal stromal cells (MSC) from nine donors ranging from infancy to young adulthood (2–32 years). Young pediatric (YP) bone marrow (+ LyP cells with B cell-biased output were enriched before age 10, whereas CD127− LyP cells with combined lymphoid and myeloid features predominated thereafter. Stromal signaling showed corresponding age-dependent changes, with increased interleukin-7 production by bone marrow MSC in YP compared to AYA, indicating niche-mediated regulation of HSPC lineage potential during ontogeny. This single-cell atlas provides a comprehensive resource for understanding hematopoietic development and early-life origins of hematologic disease.
- 17 February 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 613-623
Top Cited PapersOpen AccessSingle-cell multiomic atlas of healthy pediatric bone marrow reveals age-dependent differences in lineage differentiation driven by stromal signaling
Childhood is a critical period for hematopoietic development and susceptibility to hematologic disease. Here we generated a multimodal single-cell atlas of healthy human bone marrow, capturing mRNA and surface protein expression in 90,710 cells, including over 20,000 hematopoietic stem and progenitor cells (HSPC) and mesenchymal stromal cells (MSC) from nine donors ranging from infancy to young adulthood (2–32 years). Young pediatric (YP) bone marrow (+ LyP cells with B cell-biased output were enriched before age 10, whereas CD127− LyP cells with combined lymphoid and myeloid features predominated thereafter. Stromal signaling showed corresponding age-dependent changes, with increased interleukin-7 production by bone marrow MSC in YP compared to AYA, indicating niche-mediated regulation of HSPC lineage potential during ontogeny. This single-cell atlas provides a comprehensive resource for understanding hematopoietic development and early-life origins of hematologic disease.